Evgen Pharma PLC Poster presentation of Imperial College data
28 Marzo 2019 - 8:02AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
28 March 2019
For immediate release 28 March 2019
RNS REACH
Evgen Pharma plc
("Evgen" or "the Company")
Poster presentation from research collaboration with Imperial
College London
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce that mechanistic data from the
Company's research collaboration with Imperial College London
("Imperial") are today being presented in a poster at the ABPP
("Activity-Based Protein Profiling") 2019 symposium in Belgium.
Imperial's research work provides further insight into the
potential mechanism of action of SFX-01 in metastatic breast cancer
and identifies potential biomarkers for determining the efficacy of
SFX-01 in this indication.
The poster can be viewed via this link
http://www.evgen.com/pipeline/
Evgen's on-going collaboration with Imperial, funded principally
by an Engineering and Physical Sciences Research Council Impact
Acceleration Account grant, uses advanced chemical proteomics
technology to identify targets for SFX-01 and also to identify
potential biomarkers associated with efficacy in metastatic breast
cancer and other diseases.
Earlier this week, Evgen announced its first Phase II clinical
read-out of SFX-01 in metastatic breast cancer. The headline data
showed that SFX-01 had met its primary safety and efficacy
endpoints in the STEM open label study, marking a highly
significant step in the product's clinical development.
Steve Franklin, CEO of Evgen Pharma, said:
"We are delighted that our collaboration with Professor Tate and
Imperial College is already yielding results that will support and
inform the development of SFX-01 in metastatic breast cancer and
other diseases. Having announced positive Phase II clinical data in
this indication earlier this week, it is particularly interesting
to see results that may ultimately lead to one or more biomarkers
that could potentially be used to help identify those patients that
would be expected to have a better response to SFX-01."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
finnCap
Geoff Nash, Teddy Whiley (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
www.finncap.com +44 (0) 20 7220 0500
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Buchanan
Mark Court, Sophie Wills, Tilly
Abraham
evgen@buchanan.uk.com +44 (0) 20 7466 5000
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
The Group commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAJRMTTMBMTTFL
(END) Dow Jones Newswires
March 28, 2019 03:02 ET (07:02 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024